RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2020-08-19

Name: RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2020-08-19
Creator: RESPIRERX PHARMACEUTICALS INC.
License: https://creativecommons.org/licenses/by/4.0/

What RESPIRERX PHARMACEUTICALS INC. reported in its quarterly report filed 2020-08-19 (fiscal Q2 2020): 17 published measures, 54 facts as tagged in accession 0001493152-20-016297.

This filing

Form: 10-Q (quarterly report)
Filed: 2020-08-19
Fiscal period: fiscal Q2 2020
Accession: 0001493152-20-016297 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All RESPIRERX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-06-30	85,683	USD
At 2019-12-31	45,328	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2020-06-30	-7,846,748	USD
At 2020-03-31	-7,451,419	USD
At 2019-12-31	-7,444,819	USD
At 2019-06-30	-6,617,038	USD
At 2019-03-31	-6,227,775	USD
At 2018-12-31	-5,733,255	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2020-06-30	1,492	USD
At 2019-12-31	16,690	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2020-04-01 to 2020-06-30	-816,137	USD	91
2020-01-01 to 2020-06-30	-1,762,855	USD	182
2020-01-01 to 2020-03-31	-946,718	USD	91
2019-01-01 to 2019-12-31	2,115,033	USD	365
2019-04-01 to 2019-06-30	-477,213	USD	91
2019-01-01 to 2019-06-30	-1,017,545	USD	181
2019-01-01 to 2019-03-31	-540,332	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2020-01-01 to 2020-06-30	-106,448	USD	182
2019-01-01 to 2019-12-31	-487,745	USD	365
2019-01-01 to 2019-06-30	-266,278	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2020-01-01 to 2020-06-30	91,250	USD	182
2019-01-01 to 2019-06-30	233,000	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-06-30	-168,271,940	USD
At 2019-12-31	-166,509,085	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2020-04-01 to 2020-06-30	-616,915	USD	91
2020-01-01 to 2020-06-30	-1,137,485	USD	182
2019-04-01 to 2019-06-30	-418,391	USD	91
2019-01-01 to 2019-06-30	-892,254	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-06-30	85,683	USD
At 2019-12-31	45,328	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2020-04-01 to 2020-06-30	190,606	USD	91
2020-01-01 to 2020-06-30	331,316	USD	182
2019-04-01 to 2019-06-30	70,533	USD	91
2019-01-01 to 2019-06-30	151,645	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-06-30	7,932,431	USD
At 2019-12-31	7,490,147	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2020-04-01 to 2020-06-30	616,915	USD	91
2020-01-01 to 2020-06-30	1,137,485	USD	182
2019-04-01 to 2019-06-30	418,391	USD	91
2019-01-01 to 2019-06-30	892,254	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2020-04-01 to 2020-06-30	153,176	USD	91
2020-01-01 to 2020-06-30	308,466	USD	182
2019-04-01 to 2019-06-30	148,000	USD	91
2019-01-01 to 2019-06-30	297,350	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2020-06-30	222,307,381	shares
At 2019-12-31	4,175,072	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2020-06-30	160,181,182	USD
At 2019-12-31	159,038,388	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2020-04-01 to 2020-06-30	463,739	USD	91
2020-01-01 to 2020-06-30	829,019	USD	182
2019-04-01 to 2019-06-30	270,391	USD	91
2019-01-01 to 2019-06-30	594,904	USD	181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2020-01-01 to 2020-06-30	1,498	USD	182
2019-01-01 to 2019-06-30	932	USD	181

Inspect the source

Entity: RESPIRERX PHARMACEUTICALS INC. / CIK 0000849636
Captured: 2026-09-22 19:31 UTC
SEC response SHA-256: f692532c7d166963e2fad68da28689f5b935e4c0402c22ccfa62bc8615c926ab

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000849636.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))